Mona Kidon

Mona Kidon

Auto-generated profile, based on publicly available information

Mona Kidon

Clinical Immunology, Angioedema and Allergy Unit, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2018 in Pediatric Allergy and Immunology
Verified
Journal Article
Open access
PDF file
MKMona Kidon
Mona Kidon
NBNatalia Blanca‐Lopez
Natalia Blanca‐Lopez
EGEva Gomes
Eva Gomes
ITIngrid Terreehorst
Ingrid Terreehorst
Luciana Kase TannoLuciana Kase Tanno
Luciana Kase Tanno
MMMarina Atanasković Marković
Marina Atanasković Marković
Non‐steroidal anti‐inflammatory drugs (NSAIDs) are commonly used in the pediatric population as antipyretics/analgesics and anti‐inflammatory medications. Hypersensitivity (HS) reactions to NSAID in this age group, while similar to adults, have unique diagnostic and management issues. Although slowly accumulating, published data in this age group are still relatively rare and lacking a unifying consensus. This work is a summary of current knowledge and consensus recommendations utilizing both published data and expert opinion from the European Network of Drug Allergy (ENDA) and the Drug Hypersensitivity interest group in the European Academy of Allergy and Clinical Immunology (EAACI). This position paper summarizes diagnostic and management guidelines for children and adolescents with NSAIDs hypersensitivity.

7 February 2019 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
MMMarina Atanasković Marković
Marina Atanasković Marković
EGEva Gomes
Eva Gomes
JCJosefina Rodrigues Cernadas
Josefina Rodrigues Cernadas
GTGeorge du Toit
George du Toit
MKMona Kidon
Mona Kidon
JCJean-Christoph Caubet
Jean-Christoph Caubet

1 April 2016 in Annals of Allergy, Asthma & Immunology
Verified
Journal Article
Closed access
RRRoy Ratzon
Roy Ratzon
ARAvner Reshef
Avner Reshef
OEOri Efrati
Ori Efrati
MDMichal Deutch
Michal Deutch
RFRinat Forschmidt
Rinat Forschmidt
MKMona Iancovici Kidon
Mona Iancovici Kidon

16 August 2019 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
LGLeora Gotesdyner
Leora Gotesdyner
YZYuri Zeldin
Yuri Zeldin
DMDiti Machnes Maayan
Diti Machnes Maayan
AEAdi Efron
Adi Efron
TSTali Stauber
Tali Stauber
MKMona I Kidon
Mona I Kidon

1 March 2017 in Pediatric Neurology
Verified
Journal Article
Closed access
ANAndreea Nissenkorn
Andreea Nissenkorn
MKMona Kidon
Mona Kidon
BBBruria Ben-Zeev
Bruria Ben-Zeev

30 November 2021 in Frontiers in Pediatrics
Verified
Journal Article
Open access
MKMona I. Kidon
Mona I. Kidon
SYSoad Haj Yahia
Soad Haj Yahia
DMDiti Machnes-Maayan
Diti Machnes-Maayan
YLYael Levy
Yael Levy
SFShirli Frizinsky
Shirli Frizinsky
RHRan Hovav
Ran Hovav
Peanut allergy is an increasing concern in younger children. Available bedside diagnostic tools, i.e., prick tests with commercial extracts or peanut-containing foods have only limited predictive values. In a cohort of preschoolers with both a history of allergic reactions and sensitization to peanut proteins, we aimed to characterize the impact of skin tests with a novel composition of peanuts LPP-MH. Almost one quarter (27/110) of preschool children, with a history of allergic reactions to peanuts and positive standard IgE-mediated tests for peanut allergy, can tolerate the reintroduction of peanut proteins into their diet after resolving their allergy and, thus, can avoid adverse health outcomes associated with the false diagnosis. In the younger age group, a quarter of peanut allergic children, display a relatively high threshold, potentially enabling an easier and safer oral immunotherapy protocol in this window of opportunity in childhood. The use of the novel diagnostic skin test, LPP-MH, significantly improves the predictive value of outpatient evaluation for the outcomes of peanut challenge as well as the expected threshold at which the PA child will react, thus, making for a better informed decision of how, when, and where to challenge.